MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
MannKind (Nasdaq: MNKD) said it will release its fourth quarter and full year 2025 financial results before market open on Thursday, February 26, 2026. A live webcast reviewing results and providing a business update will begin at 9:00 a.m. ET.
The webcast will be accessible via MannKind's investor website link and a replay will be available within 24 hours and remain accessible for about 90 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MNKD declined 1.81%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MNKD is down 2.12% with mixed peer moves: ARDX down 3.57%, while AUPH, VCEL, HRMY, and SRPT are modestly positive. No sector-wide momentum flags this as stock-specific rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Pediatric trial start | Positive | +2.3% | First patient enrolled in INHALE-1ST pediatric Afrezza study with PDUFA pending. |
| Jan 26 | Label update approval | Positive | +2.2% | FDA approved updated Afrezza label with dosing conversion guidance for switches. |
| Jan 08 | Business update | Positive | +2.7% | Business update highlighting record Q4 revenue and 2026 growth drivers. |
| Dec 23 | FUROSCIX update | Positive | -1.0% | FUROSCIX pediatric approval and new patents with extended IP and PDUFA date. |
| Dec 01 | sNDA acceptance | Positive | +1.5% | FDA accepted FUROSCIX ReadyFlow sNDA with supportive PK and bioavailability data. |
Recent MannKind news, especially regulatory and clinical updates, has mostly seen positive price alignment, with one divergence on a FUROSCIX update.
Over the past few months, MannKind has reported several positive milestones. In Q3 2025, it highlighted strong growth drivers and a record quarter with net revenue above $100 million. Subsequent regulatory wins included FDA acceptance of the FUROSCIX ReadyFlow sNDA with a PDUFA date of July 26, 2026 and an updated Afrezza label approved on January 26, 2026. Shares generally reacted positively to these events, suggesting investors have rewarded progress in Afrezza and FUROSCIX ahead of upcoming catalysts. Today’s earnings-date notice fits into this ongoing execution narrative.
Market Pulse Summary
This announcement simply schedules MannKind’s fourth quarter and full year 2025 results for February 26, 2026, with a webcast at 9:00 a.m. Eastern Time and a replay available within 24 hours for about 90 days. In context, it follows several months of positive regulatory and clinical milestones. Investors typically watch such calls for updates on Afrezza, FUROSCIX programs, and integration of scPharmaceuticals, as well as progress against prior growth drivers.
AI-generated analysis. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and will be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts: Investor Relations Kate Miranda (617) 921-5461 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com
FAQ
When will MannKind (MNKD) report Q4 and full year 2025 financial results?
What time is the MannKind (MNKD) webcast to discuss February 26, 2026 results?
Where can investors access the MannKind (MNKD) February 26, 2026 webcast?
Will a replay of the MannKind (MNKD) February 26, 2026 webcast be available?
What will MannKind (MNKD) cover during the February 26, 2026 webcast?
